Compounds > imatinib mesylate
Page last updated: 2024-09-03

imatinib mesylate and Ewing Sarcoma

imatinib mesylate has been researched along with Ewing Sarcoma in 19 studies

Research

Studies (19)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's14 (73.68)29.6817
2010's4 (21.05)24.3611
2020's1 (5.26)2.80

Authors

AuthorsStudies
Carcaboso, ÁM; Castillo-Ecija, H; Kumarasamy, M; Peled, E; Sosnik, A; Sverdlov Arzi, R; Zaritski, A1
Cheng, H; Lau, CC; Nan, X; Qiu, B; Sheng, J; Wang, J; Wong, STC; Yin, Z; Yustein, JT; Zhao, H1
Blay, JY; Cassier, P; Dufresne, A; Heudel, P; Pissaloux, D; Ray-Coquard, I; Wang, Q1
Caballero, G; de Alava, E; García-Sánchez, A; Herrero, D; Mackintosh, C; Madoz-Gúrpide, J; Martins, AS; Ordoñez, JL; Osuna, D; Otero, AP; Poremba, C; Sevillano, V1
Budd, GT; Chao, J; Chow, WA; Chu, P; Frankel, P; Garcia, D; Junqueira, M; Loera, S; Sato, J; Somlo, G1
Hayes-Jordan, A; Kleinerman, ES; Lev, D; Mandal, D; Pollock, RE; Wang, S; Wang, Y1
Boos, J; Hotfilder, M; Jürgens, H; Lanvers, C; Vormoor, J1
Adams, R; Albritton, K; Coffin, C; Goldsby, R; Pulsipher, M; Wagner, L1
Druker, BJ1
Mackall, CL; Merchant, MS; Thiele, CJ; Woo, CW1
Astolfi, A; Benini, S; Bertoni, F; Landuzzi, L; Lollini, PL; Manara, MC; Nanni, P; Nicoletti, G; Perdichizzi, S; Picci, P; Scotlandi, K; Serra, M; Strammiello, R1
Albertini, V; Bonadiman, L; Pierotti, MA; Pilotti, S; Tamborini, E1
Andreu, EJ; de Alava, E; Fernández-Luna, JL; Fontalba, A; Gaboli, M; González, I; Inogés, S; Martín-Algarra, S; Panizo, A; Pardo, J; Prósper, F; Sierrasesúmaga, L1
Basso, G; Crescenzio, N; Ricotti, E; Rinaldi, A; Rosolen, A; Spinelli, M; Te Kronnie, G; Timeus, F1
Bakhanashvili, M; Beery, E; Birenbaum, M; Fenig, E; Lahav, M; Luria, D; Nordenberg, J; Reshef, H; Sandbank, J; Uziel, O; Yerushalmi, R1
Campos, M; de Alava, E; Hernández, T; Mackintosh, C; Martín, DH; Martins, AS; Ordóñez, JL1
Adamson, PC; Bernstein, ML; Blaney, SM; Bond, M; Krailo, M; Pappo, A; Schultz, KR1
Araujo, ES; Bacchini, P; Bertoni, F; Do, I; Kalil, RK; Park, YK; Unni, KK1
Beery, E; Fenig, E; Lahav, M; Luria, D; Nordenberg, J; Uziel, O; Yerushalmi, R1

Reviews

1 review(s) available for imatinib mesylate and Ewing Sarcoma

ArticleYear
[Molecular biology of sarcoma and therapeutic choices].
    Bulletin du cancer, 2015, Volume: 102, Issue:1

    Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Benzamides; Bone Neoplasms; Crizotinib; Denosumab; Dermatofibrosarcoma; Gastrointestinal Stromal Tumors; Gene Amplification; Gene Deletion; Giant Cell Tumor of Bone; Humans; Imatinib Mesylate; Indoles; Molecular Targeted Therapy; Phenylurea Compounds; Piperazines; Point Mutation; Prognosis; Pyrazoles; Pyridines; Pyrimidines; Pyrroles; Sarcoma; Sarcoma, Ewing; Sunitinib; Synovitis, Pigmented Villonodular; Translocation, Genetic

2015

Trials

2 trial(s) available for imatinib mesylate and Ewing Sarcoma

ArticleYear
Phase II clinical trial of imatinib mesylate in therapy of KIT and/or PDGFRalpha-expressing Ewing sarcoma family of tumors and desmoplastic small round cell tumors.
    Anticancer research, 2010, Volume: 30, Issue:2

    Topics: Abdominal Neoplasms; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Benzamides; Bone Neoplasms; Carcinoma, Small Cell; Female; Humans; Imatinib Mesylate; Male; Middle Aged; Neuroectodermal Tumors, Primitive; Piperazines; Proto-Oncogene Proteins c-kit; Pyrimidines; Receptor, Platelet-Derived Growth Factor beta; Sarcoma, Ewing; Survival Rate; Treatment Outcome

2010
A phase II study of imatinib mesylate in children with refractory or relapsed solid tumors: a Children's Oncology Group study.
    Pediatric blood & cancer, 2008, Volume: 50, Issue:2

    Topics: Adolescent; Adult; Antineoplastic Agents; Benzamides; Bone Neoplasms; Carcinoma, Small Cell; Child; Child, Preschool; Female; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Male; Neoplasm Recurrence, Local; Neoplasms; Neuroblastoma; Osteosarcoma; Piperazines; Pyrimidines; Sarcoma, Ewing; Sarcoma, Synovial

2008

Other Studies

16 other study(ies) available for imatinib mesylate and Ewing Sarcoma

ArticleYear
Selective Accumulation of Galactomannan Amphiphilic Nanomaterials in Pediatric Solid Tumor Xenografts Correlates with
    ACS applied materials & interfaces, 2019, Oct-23, Volume: 11, Issue:42

    Topics: Animals; Cell Line, Tumor; Cell Survival; Child; Drug Carriers; Galactose; Glucose Transporter Type 1; Heterografts; Humans; Imatinib Mesylate; Mannans; Mice; Microscopy, Confocal; Nanoparticles; Polymethyl Methacrylate; Protein Kinase Inhibitors; Sarcoma, Ewing; Tissue Distribution

2019
Imatinib revives the therapeutic potential of metformin on ewing sarcoma by attenuating tumor hypoxic response and inhibiting convergent signaling pathways.
    Cancer letters, 2020, 01-28, Volume: 469

    Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Bone Neoplasms; Breast Neoplasms; Cell Cycle Checkpoints; Cell Hypoxia; Cell Line, Tumor; Drug Synergism; Female; Gene Expression Regulation, Neoplastic; Glioblastoma; Humans; Imatinib Mesylate; Male; Metformin; Mice; Oncogene Proteins, Fusion; Ovarian Neoplasms; Phosphatidylinositol 3-Kinases; Progression-Free Survival; Proto-Oncogene Protein c-fli-1; Proto-Oncogene Proteins c-akt; RNA-Binding Protein EWS; RNA-Seq; Sarcoma, Ewing; Signal Transduction; TOR Serine-Threonine Kinases; Xenograft Model Antitumor Assays

2020
A pivotal role for heat shock protein 90 in Ewing sarcoma resistance to anti-insulin-like growth factor 1 receptor treatment: in vitro and in vivo study.
    Cancer research, 2008, Aug-01, Volume: 68, Issue:15

    Topics: Antineoplastic Agents; Apoptosis; Benzamides; Blotting, Western; Cell Proliferation; Drug Resistance, Neoplasm; Electrophoresis, Gel, Two-Dimensional; HSP90 Heat-Shock Proteins; Humans; Imatinib Mesylate; In Vitro Techniques; Piperazines; Pyrimidines; Pyrroles; Receptor, IGF Type 1; Sarcoma, Ewing

2008
Platelet-derived growth factor receptor beta inhibition increases tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) sensitivity: imatinib and TRAIL dual therapy.
    Cancer, 2010, Aug-15, Volume: 116, Issue:16

    Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Humans; Imatinib Mesylate; Mice; Mice, Nude; Neoplasm Metastasis; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Receptor, Platelet-Derived Growth Factor beta; Sarcoma, Ewing; TNF-Related Apoptosis-Inducing Ligand; Tumor Cells, Cultured

2010
c-KIT-expressing Ewing tumour cells are insensitive to imatinib mesylate (STI571).
    Cancer chemotherapy and pharmacology, 2002, Volume: 50, Issue:2

    Topics: Antineoplastic Agents; Benzamides; Bone Neoplasms; Drug Resistance, Neoplasm; Enzyme Inhibitors; Humans; Imatinib Mesylate; Neoplasm Proteins; Piperazines; Protein-Tyrosine Kinases; Proto-Oncogene Proteins c-kit; Pyrimidines; Reverse Transcriptase Polymerase Chain Reaction; Sarcoma, Ewing; Signal Transduction; Tumor Cells, Cultured

2002
Unexpected pleural effusions in 3 pediatric patients treated with STI-571.
    Journal of pediatric hematology/oncology, 2002, Volume: 24, Issue:8

    Topics: Adolescent; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Bone Marrow Transplantation; Camptothecin; Child; Combined Modality Therapy; Edema; Enzyme Inhibitors; Etoposide; Female; Granulocyte-Macrophage Colony-Stimulating Factor; Hematopoietic Stem Cell Transplantation; Humans; Imatinib Mesylate; Irinotecan; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemic Infiltration; Lung Neoplasms; Male; Neoplasm Proteins; Neuroectodermal Tumors, Primitive; Piperazines; Pleural Effusion; Proto-Oncogene Proteins c-kit; Pyrimidines; Remission Induction; Sarcoma, Ewing; Testis; Topotecan

2002
Taking aim at Ewing's sarcoma: is KIT a target and will imatinib work?
    Journal of the National Cancer Institute, 2002, Nov-20, Volume: 94, Issue:22

    Topics: Antineoplastic Agents; Benzamides; Bone Neoplasms; Clinical Trials, Phase I as Topic; Dose-Response Relationship, Drug; Enzyme Inhibitors; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Protein-Tyrosine Kinases; Proto-Oncogene Proteins c-kit; Pyrimidines; Sarcoma, Ewing; Treatment Outcome; Tumor Cells, Cultured

2002
Potential use of imatinib in Ewing's Sarcoma: evidence for in vitro and in vivo activity.
    Journal of the National Cancer Institute, 2002, Nov-20, Volume: 94, Issue:22

    Topics: Animals; Antineoplastic Agents; Apoptosis; Benzamides; Bone Neoplasms; Disease Models, Animal; Enzyme Inhibitors; Gene Expression Regulation, Neoplastic; Humans; Imatinib Mesylate; Immunoblotting; Inhibitory Concentration 50; Phosphorylation; Piperazines; Precipitin Tests; Protein-Tyrosine Kinases; Proto-Oncogene Proteins c-kit; Pyrimidines; Sarcoma, Ewing; Stem Cell Factor; Time Factors; Transplantation, Heterologous; Tumor Cells, Cultured

2002
C-kit receptor expression in Ewing's sarcoma: lack of prognostic value but therapeutic targeting opportunities in appropriate conditions.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2003, May-15, Volume: 21, Issue:10

    Topics: Antineoplastic Agents; Benzamides; Biomarkers, Tumor; Bone Neoplasms; Cell Division; Cell Movement; Child; Doxorubicin; Drug Synergism; Enzyme Inhibitors; Female; Gene Expression Regulation, Neoplastic; Humans; Imatinib Mesylate; Male; Piperazines; Prognosis; Protein-Tyrosine Kinases; Proto-Oncogene Proteins c-kit; Pyrimidines; Sarcoma, Ewing; Survival Analysis; Tumor Cells, Cultured

2003
Re: Potential use of imatinib in Ewing's sarcoma: evidence for in vitro and in vivo activity.
    Journal of the National Cancer Institute, 2003, Jul-16, Volume: 95, Issue:14

    Topics: Antineoplastic Agents; Benzamides; Bone Neoplasms; Enzyme Inhibitors; Gene Expression Regulation, Neoplastic; Humans; Imatinib Mesylate; In Vitro Techniques; Oncogene Proteins; Phosphorylation; Piperazines; Precipitin Tests; Proto-Oncogene Proteins c-kit; Pyrimidines; Reverse Transcriptase Polymerase Chain Reaction; Sarcoma, Ewing

2003
Imatinib inhibits proliferation of Ewing tumor cells mediated by the stem cell factor/KIT receptor pathway, and sensitizes cells to vincristine and doxorubicin-induced apoptosis.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 2004, Jan-15, Volume: 10, Issue:2

    Topics: Antibiotics, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Apoptosis; Benzamides; Blotting, Western; Bone Neoplasms; Cell Division; Cell Line, Tumor; Dose-Response Relationship, Drug; Doxorubicin; Enzyme Inhibitors; Flow Cytometry; Humans; Imatinib Mesylate; Immunohistochemistry; Indicators and Reagents; Inhibitory Concentration 50; Ligands; Mitogen-Activated Protein Kinase 1; Mitogen-Activated Protein Kinase 3; Mitogen-Activated Protein Kinases; Phosphorylation; Piperazines; Precipitin Tests; Propidium; Proto-Oncogene Proteins c-kit; Pyrimidines; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Sarcoma, Ewing; Signal Transduction; Stem Cell Factor; Vincristine

2004
Imatinib mesylate (STI571) interference with growth of neuroectodermal tumour cell lines does not critically involve c-Kit inhibition.
    International journal of molecular medicine, 2004, Volume: 14, Issue:3

    Topics: Animals; Annexin A5; Antineoplastic Agents; Apoptosis; Benzamides; Caspase 3; Caspases; Cell Division; Cell Line, Tumor; Cell Transplantation; Dose-Response Relationship, Drug; Enzyme-Linked Immunosorbent Assay; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Imatinib Mesylate; Mice; Mice, Nude; Mice, SCID; Neoplasm Transplantation; Neuroblastoma; Neuroectodermal Tumors; Phosphorylation; Piperazines; Proto-Oncogene Proteins c-kit; Pyrimidines; Reactive Oxygen Species; Sarcoma, Ewing; Time Factors; Transplantation, Heterologous; Tumor Burden

2004
Imatinib mesylate (Gleevec) downregulates telomerase activity and inhibits proliferation in telomerase-expressing cell lines.
    British journal of cancer, 2005, May-23, Volume: 92, Issue:10

    Topics: Animals; Antineoplastic Agents; Benzamides; Breast Neoplasms; Cell Proliferation; Dose-Response Relationship, Drug; Down-Regulation; Fanconi Anemia; Humans; Imatinib Mesylate; Melanoma; Mice; Multiple Myeloma; Piperazines; Protein-Tyrosine Kinases; Pyrimidines; Sarcoma, Ewing; Skin Neoplasms; Telomerase; Tumor Cells, Cultured

2005
Insulin-like growth factor I receptor pathway inhibition by ADW742, alone or in combination with imatinib, doxorubicin, or vincristine, is a novel therapeutic approach in Ewing tumor.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 2006, Jun-01, Volume: 12, Issue:11 Pt 1

    Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Benzamides; Bone Neoplasms; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Dose-Response Relationship, Drug; Down-Regulation; Doxorubicin; Drug Screening Assays, Antitumor; G1 Phase; Humans; Imatinib Mesylate; Phosphorylation; Piperazines; Protein Kinases; Proto-Oncogene Proteins c-akt; Pyrimidines; Pyrroles; Receptor, IGF Type 1; Sarcoma, Ewing; Structure-Activity Relationship; TOR Serine-Threonine Kinases; Vincristine

2006
Protein expression of KIT and gene mutation of c-kit and PDGFRs in Ewing sarcomas.
    Pathology, research and practice, 2007, Volume: 203, Issue:3

    Topics: Adolescent; Adult; Antineoplastic Agents; Benzamides; Bone Neoplasms; Child; Child, Preschool; DNA Mutational Analysis; Exons; Female; Gene Expression Regulation, Neoplastic; Humans; Imatinib Mesylate; Immunohistochemistry; Infant; Korea; Male; Middle Aged; Mutation; Paraffin Embedding; Patient Selection; Piperazines; Proto-Oncogene Proteins c-kit; Pyrimidines; Receptor, Platelet-Derived Growth Factor alpha; Receptor, Platelet-Derived Growth Factor beta; Receptors, Platelet-Derived Growth Factor; Sarcoma, Ewing

2007
Combined antiproliferative activity of imatinib mesylate (STI-571) with radiation or cisplatin in vitro.
    Experimental oncology, 2007, Volume: 29, Issue:2

    Topics: Antineoplastic Agents; Apoptosis; Benzamides; Blotting, Western; Breast Neoplasms; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Cisplatin; Combined Modality Therapy; Dose-Response Relationship, Drug; Drug Synergism; Enzyme-Linked Immunosorbent Assay; Flow Cytometry; Fluorescent Dyes; Humans; Imatinib Mesylate; In Vitro Techniques; Inhibitory Concentration 50; Phosphorylation; Piperazines; Proto-Oncogene Proteins c-akt; Pyrimidines; Rhodamines; Sarcoma, Ewing

2007